Dr. Humes’ laboratory has a long-standing interest in tissue engineering and renal replacement technology. The laboratory has developed a bioartificial kidney that is currently in Phase II clinical trials. This biotechnologic device is dependent upon: a) stem cell technology to select and grow renal tubule epithelial stem cells derived from human tissue; b) biomaterials development for improved biocompatibility and transport capabilities; and c) bioreactor cell culture methodology. This is the first step in the development of an implantable bioartificial kidney. His group is also developing prototypes for an implantable bioartificial hemofilter to replace the glomerular function of the kidney. A second area of interest is the development of a cell therapy intravascular device to permit implantation of cells for regulated hormone production (e.g., insulin and erythropoietin) or use of cells as a gene therapy delivery vehicle (e.g., hemophilia-A and -B). This research program utilizes stem cell technology, biomaterials research, bioreactor development, and stable gene transfer methodology to develop tissue engineering constructs for tissue replacement therapy and treatment of genetic diseases.
Link to PubMed Citations
Tumlin J, Wali R, Williams W, Murray P, Tolwani AJ, Vinnikova AK , et al. Efficacy and safety of renal tubule cell therapy for acute renal failure. J Am Soc Nephrol 2008; 19:1034–1040.
Fissell WH, Fleischman AJ, Humes HD, and Roy S. Development of continuous implantable renal replacement: Past and Future. Translational Res 2007; 150:327–336.
Tiranathanagul K, Dhawan V, Lytle IF, Zhang W, Borschel GH, Buffington DA, Tziampazis E, Brown DL, and Humes HD. Tissue engineering of an implantable bioartificial hemofilter. ASAIO J 2007;53:176–186.
Fissell WH, Humes HD, Fleischman AJ, and Roy S. Dialysis and nanotechnology: Now, 10 years, or never? Blood Purif 2007; 25:12–17.
Fissell WH, Manley S, Westover A, Humes HD, Fleischman AJ, and Roy S. Differentiated growth of human renal tubule cells on thin-film and nanostructured materials. ASAIO J 2006;52:221–227.
Humes HD, Fissell W, and Tiranathanagul K. The future of hemodialysis membranes. Kidney Int 2006;69:1115–1119.
Brodie JC and Humes HD. Stem cell approaches for the treatment of renal failure. Pharmacol Rev 2005;57:299–313.
Szczypka MS, Westover AJ, Clouthier SG, Ferrara JLM, and Humes HD. Rare incorporation of bone marrow-derived cells into kidney after folic acid-induced injury. Stem Cells 2005;23:44–54.
Humes HD. Translational medicine and the National Institutes of Health road map: Steep grades and tortuous curves. J Lab Clin Med 2005;146:51–54.
Nallamothu BK, Shojania KG, Saint S, Hofer TP, Humes HD, Moscucci M, Bates ER. Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis. Am J Med 2004;117:938–947.
Humes HD, Weitzel WF, Bartlett RH, Swaniker FC, Paganini EP, Luderer JR, and Sobota J. Initial clinical results of the bioartificial kidney containing human cells in ICU patients with acute renal failure. Kidney Int 2004;66:1578–1588.
Tiranathanagul K, Brodie JC, and Humes HD. Bioartificial kidney in the treatment of acute renal failure associated with sepsis. Nephrology 2006;11:285–291.
Low J, Humes HD, Szczypka M, and Imperiale M. BKV and SV40 infection of human kidney tubular epithelial cells in vitro. Virology 2004;323(2):182–188.
Humes HD and Szczypka MS. Advances in cell therapy for renal failure. Transplant Immunology 2004;12:219–227.
Humes HD, Weitzel WF, Fissell WH. Renal cell therapy in the treatment of patients with acute and chronic renal failure. Blood Purif 2004;22:60–72.